Ebru Koca1, Richard E Champlin. 1. Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. ekoca@mdanderson.org
Abstract
PURPOSE OF REVIEW: The paper compares bone marrow and peripheral blood progenitor cell transplantations in the allogeneic setting. RECENT FINDINGS: Peripheral blood progenitor cell use has emerged as an international standard of care for hematopoietic transplantation. These cells have a different cellular composition including higher numbers of CD34 cells and markedly higher numbers of T lymphocytes. Current data support the general safety of this approach for normal transplant donors. Results consistently indicate more rapid hematopoietic recovery compared with bone marrow transplantation. This may result in improved early survival in adults with high-risk leukemias, but longer follow-up has demonstrated an increased rate of chronic graft-versus-host disease morbidity and mortality which may obviate the long-term benefit. SUMMARY: It is unclear whether peripheral blood progenitor cell or bone marrow transplantation will produce improved disease-free or overall survival. Additional studies with long-term follow-up are necessary to resolve these controversies.
PURPOSE OF REVIEW: The paper compares bone marrow and peripheral blood progenitor cell transplantations in the allogeneic setting. RECENT FINDINGS: Peripheral blood progenitor cell use has emerged as an international standard of care for hematopoietic transplantation. These cells have a different cellular composition including higher numbers of CD34 cells and markedly higher numbers of T lymphocytes. Current data support the general safety of this approach for normal transplant donors. Results consistently indicate more rapid hematopoietic recovery compared with bone marrow transplantation. This may result in improved early survival in adults with high-risk leukemias, but longer follow-up has demonstrated an increased rate of chronic graft-versus-host disease morbidity and mortality which may obviate the long-term benefit. SUMMARY: It is unclear whether peripheral blood progenitor cell or bone marrow transplantation will produce improved disease-free or overall survival. Additional studies with long-term follow-up are necessary to resolve these controversies.
Authors: Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-04-24 Impact factor: 5.742
Authors: David Gallardo; Rafael de la Cámara; Jose B Nieto; Ildefonso Espigado; Arturo Iriondo; Antonio Jiménez-Velasco; Carlos Vallejo; Carmen Martín; Dolores Caballero; Salut Brunet; David Serrano; Carlos Solano; Josep M Ribera; Javier de la Rubia; Enric Carreras Journal: Haematologica Date: 2009-09 Impact factor: 9.941
Authors: João Tadeu Ribeiro-Paes; Aldemir Bilaqui; Oswaldo T Greco; Milton Artur Ruiz; Monica Y Marcelino; Talita Stessuk; Carolina A de Faria; Mario R Lago Journal: Int J Chron Obstruct Pulmon Dis Date: 2011-01-01